GlassScriptPhysician profile
Zachary Taich
NPI 1174055180
$7,284.59
in general payments reported to CMS, 2019-2025
19 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $121 · 2023: $6,312 · 2024: $456 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $1,009 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $1,008.53 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,200.27 | 2023-2024 | Da Vinci Surgical System, Ion |
| Inspire Medical Systems, INC. | $176.94 | 2022-2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.77 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $157.66 | 2023-2025 | Fasenra, Breztri, Tezspire |
| Jazz Pharmaceuticals INC. | $114.38 | 2023 | |
| Glaxosmithkline, LLC. | $77.88 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $57.88 | 2024 | Dupixent |
| Harmony Biosciences LLC | $42.93 | 2024 | |
| Insmed, INC. | $38.62 | 2025 | Arikayce |
| Inogen, INC. | $36.63 | 2024 | |
| Viatris Specialty LLC | $34.41 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $27.53 | 2025 | Lumryz |
| Philips North America LLC | $26.03 | 2024 | (8874) Incourage |
| Baxter Healthcare | $24.94 | 2025 | |
| Lilly USA, LLC | $21.78 | 2025 | Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $21.33 | 2025 | Ohtuvayre |
| Genzyme Corporation | $20.29 | 2024 | |
| Grifols USA, LLC | $18.82 | 2024 | Prolastin-C Liquid |
| Phadia US INC. | $14.50 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Taich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.